Quick answer:
Methylene blue is a redox-active compound that may influence oxidative stress by changing how electrons move through cells. Depending on concentration and biological conditions, it can reduce or increase reactive oxygen species (ROS). Laboratory studies have explored its effects on mitochondrial function, while small human studies have examined memory and mood. Morgan Compounding Pharmacy prepares patient-specific methylene blue capsules and oral suspensions for Georgia prescribers.
Calling methylene blue an antioxidant tells only part of the story. Its unique redox properties, which allow it to accept and transfer electrons, have researchers taking a closer look at how it influences mitochondrial function and oxidative stress.
While FDA-approved intravenous methylene blue has an established medical use in acquired methemoglobinemia, newer research is exploring other potential applications. Recent laboratory findings and small human studies have raised questions about its role in cellular energy, memory, and mood.
For patients and prescribers, understanding how methylene blue’s redox activity works provides useful context for discussing oral formulations, including available capsules, suspensions, and medication considerations.
Is Methylene Blue an Antioxidant?
Methylene blue can exhibit antioxidant properties, but its activity depends on the biological environment and concentration.
Cells naturally produce reactive oxygen species (ROS), including superoxide and hydrogen peroxide, during metabolism. Controlled amounts contribute to normal cell signaling. However, oxidative stress occurs when reactive activity exceeds the body’s protective capacity, potentially affecting proteins, cell membranes, and DNA.
Methylene blue can influence this balance through oxidation-reduction (redox) reactions. Its ability to accept and donate electrons may change how ROS are generated within cells.
This makes methylene blue different from traditional antioxidants. Under certain experimental conditions, it may reduce oxidative activity. Under others, the same electron-transfer process can contribute to ROS production.
How Methylene Blue Affects Mitochondria and Oxidative Stress
Mitochondria help cells produce adenosine triphosphate (ATP), which supplies energy for normal cellular activity.
Methylene blue can influence this process through redox cycling. It accepts electrons and transfers them to other molecules, potentially changing how electrons move through mitochondria.
This activity may affect mitochondrial respiration and the production of reactive oxygen species. Researchers have investigated these effects to better understand methylene blue’s relationship with oxidative stress.
What Does Methylene Blue Antioxidant Research Show?
Laboratory research has examined how methylene blue affects mitochondrial electron flow and reactive oxygen species. Several experiments show that its activity changes with concentration and biological conditions.
Electron Transfer and ROS Production
- Alternative mitochondrial pathway: The 2011 study found that methylene blue supported alternative electron transfer and increased oxygen consumption in cultured neuronal cells. These findings demonstrate its ability to influence cellular energy metabolism.
- ROS generation through enzymes: A 2008 biochemical study examined methylene blue’s interaction with human disulfide reductases and related enzymes. In certain reactions, redox cycling generated hydrogen peroxide, demonstrating that its activity can also contribute to ROS production.
Concentration-Dependent and Human-Tissue Findings
- Human cardiovascular tissue: In a 2025 pilot study, researchers collected adipose tissue from 25 patients with heart failure undergoing cardiac surgery. They exposed the samples to 0.1 micromolar methylene blue for 24 hours and measured lower monoamine oxidase expression and oxidative-stress markers. The experiments took place in the laboratory, not in the patients.
- Isolated brain mitochondria: A 2026 study investigated concentration-dependent responses in isolated brain mitochondria. At 1 micromolar, methylene blue increased hydrogen peroxide production without significantly changing oxygen consumption under the studied conditions. Other concentrations produced different mitochondrial responses.
These studies demonstrate why methylene blue’s antioxidant activity depends on the concentration, tissue, and biological pathway being examined.
What Have Human Studies Found About Methylene Blue?
Small human studies have explored oral methylene blue’s relationship with cognitive function and mood-related symptoms. These studies used specific doses and patient populations, offering early insight into potential applications.
Memory and Cognitive Function
A 2016 randomized study examined oral methylene blue in 26 healthy adults. Thirteen participants received a single 280 mg dose, approximately 4 mg/kg, while the others received placebo.
Researchers observed increased brain activity during attention and memory tasks. They also reported a 7% increase in correct responses during memory retrieval, providing early human evidence of potential short-term cognitive effects.
Mood-Related Processes
A randomized crossover study involving 37 adults with bipolar disorder investigated oral methylene blue alongside lamotrigine. Researchers compared daily doses of 195 mg and 15 mg during separate study periods.
The higher dose was associated with improvements in depressive and anxiety symptoms. However, cognitive outcomes did not significantly improve.
Oral Methylene Blue: Dosing and Clinical Considerations
Published studies have used different oral methylene blue doses based on their research objectives and patient populations. However, these regimens do not establish a standard oral dosage for antioxidant support.
When evaluating an oral prescription, providers should consider the patient’s health history, current medications, and individual formulation needs.
Medication Interactions and Patient Considerations
Methylene blue has pharmacological activity that warrants review of the patient’s medical and medication history.
Important considerations include:
- Serotonergic drug interactions: Methylene blue inhibits monoamine oxidase A (MAO-A), creating a risk of serotonin toxicity when combined with certain medications. These include SSRIs, SNRIs, MAO inhibitors, certain opioids, dextromethorphan, and other serotonergic drugs. A published case report also describes serotonin toxicity associated with an oral methylene-blue-containing medication used alongside multiple serotonergic drugs.
- G6PD deficiency and hypersensitivity: Methylene blue can cause hemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency and is contraindicated in these patients under FDA-approved intravenous labeling. Providers should also assess any history of severe hypersensitivity to methylene blue or related thiazine dyes.
- Oral tolerability: Reported effects include temporary blue-green urine discoloration and gastrointestinal discomfort. Patients may benefit from discussing these possibilities before beginning a prescribed oral formulation.
A patient-specific medication review helps prescribers evaluate whether oral methylene blue is appropriate.
Compounded Methylene Blue Capsules and Oral Suspensions
Morgan Compounding Pharmacy prepares patient-specific oral methylene blue prescriptions for Georgia healthcare providers. The choice of capsule strength or liquid formulation depends on the prescribed dose and how the patient can take the medication.
These options allow prescribers to request a particular strength or dosage form based on individual prescription requirements.
Compounded Methylene Blue Capsule Strengths
| Formulation | Available Strength Options |
|---|---|
| Methylene blue capsules | 1 mg, 10 mg, 25 mg, 50 mg |
| Custom methylene blue capsules | Prescriber-specified strength in mg |
Prescribers can request one of the listed capsule strengths or specify a custom strength in milligrams. Our pharmacists can review the requested formulation and ingredient requirements.
Compounded Methylene Blue Oral Suspensions
Oral suspensions provide a liquid option for patients who have difficulty swallowing capsules or require a liquid dosage form.
Prescribers can consult our pharmacists about the requested concentration, formulation ingredients, and preparation requirements.
For additional information about our services, explore Methylene Blue at Morgan Compounding Pharmacy.
How to Use and Store Oral Methylene Blue
Patients should take compounded methylene blue according to their prescription instructions. For oral suspensions, use the measuring device supplied or recommended by the pharmacist and follow any shaking instructions on the label.
Store each preparation as directed and observe its assigned beyond-use date. Storage and handling requirements may differ between capsules and suspensions, so patients should contact the pharmacy with questions about their specific preparation.
Related Reading: Georgia’s Methylene Blue Compounding Pharmacy Experts
Frequently Asked Questions About Methylene Blue and Oxidative Stress
Does Oral Methylene Blue Reduce Oxidative Stress in People?
Laboratory and human-tissue studies have reported changes in oxidative-stress measurements following methylene blue exposure. However, these findings do not establish that taking oral methylene blue reliably reduces oxidative stress in patients. Human research is still developing.
Can Methylene Blue Be Taken With Antidepressants?
Methylene blue inhibits MAO-A and can interact with serotonergic medications, including certain antidepressants. These interactions may cause serious serotonin toxicity. Prescribers should review all medications and supplements before considering oral methylene blue.
Can Prescribers Request Custom Methylene Blue Capsule Strengths?
Yes. In addition to our listed capsule strengths, prescribers can request a custom strength in milligrams. Our pharmacists can discuss formulation feasibility and preparation requirements for the individual prescription.
What Is the Difference Between Methylene Blue Capsules and Oral Suspensions?
Capsules provide a solid oral dosage form, while suspensions provide a liquid option. A suspension may be appropriate for patients who have difficulty swallowing capsules or require a liquid preparation. The prescriber and pharmacist can determine which dosage form meets the patient’s needs.
Explore Our Methylene Blue Blog Series
This article is Part 1 of our four-part Methylene Blue Blog Series, exploring the science behind methylene blue and its emerging research applications.
Coming next: Part 2 – Methylene Blue & Neuroprotection: Brain Fog, followed by articles exploring Parkinson’s disease research and psychiatric applications.
Subscribe to our blog to stay informed and be notified when the next article in the series is published.
Discuss Methylene Blue Compounding With Our Pharmacists
Morgan Compounding Pharmacy supports Georgia prescribers with patient-specific methylene blue capsules and oral suspensions.
Healthcare providers can contact our pharmacists to discuss available strengths, custom formulations, ingredient requirements, and prescription preparation.
Patients interested in oral methylene blue should discuss their medication history, potential interactions, and dosage-form needs with their healthcare provider before considering a prescription.
Since 1985, Morgan Compounding Pharmacy has served Georgia communities, including Alpharetta, Roswell, Johns Creek, and Atlanta.
Call 770-475-8903 to speak with our pharmacy team.
Georgia prescribers can explore our Practitioner Resources or request access to our Methylene Blue & Low Dose Naltrexone Rx Order Form.
References
Aburel, O.-M., Brăescu, L., Buriman, D. G., Merce, A. P., Bînă, A. M., Borza, C., Mornoș, C., Sturza, A., & Muntean, D. M. (2025). Methylene blue reduces monoamine oxidase expression and oxidative stress in human cardiovascular adipose tissue. Molecular and Cellular Biochemistry, 480(4), 2413–2421. Study
Alda, M., McKinnon, M., Blagdon, R., Garnham, J., MacLellan, S., O’Donovan, C., Hajek, T., Nair, C., Dursun, S., & MacQueen, G. (2017). Methylene blue treatment for residual symptoms of bipolar disorder: Randomised crossover study. The British Journal of Psychiatry, 210(1), 54–60. Study
Buchholz, K., Schirmer, R. H., Eubel, J. K., Akoachere, M. B., Dandekar, T., Becker, K., & Gromer, S. (2008). Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 52(1), 183–191. Study
Fišar, Z., Škutová, K., & Hroudová, J. (2026). Methylene blue modulates mitochondrial electron flow via multiple regulatory sites in isolated brain mitochondria: Implications for neurodegeneration. Experimental and Molecular Pathology, 148, Article 105080. Study
Ramsay, R. R., Dunford, C., & Gillman, P. K. (2007). Methylene blue and serotonin toxicity: Inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. British Journal of Pharmacology, 152(6), 946–951. Study
Rodriguez, P., Zhou, W., Barrett, D. W., Altmeyer, W., Gutierrez, J. E., Li, J., Lancaster, J. L., Gonzalez-Lima, F., & Duong, T. Q. (2016). Multimodal randomized functional MR imaging of the effects of methylene blue in the human brain. Radiology, 281(2), 516–526. Study
U.S. Food and Drug Administration. (2024). Provayblue (methylene blue) injection, USP, for intravenous use [Prescribing information]. Link
Wen, Y., Li, W., Poteet, E. C., Xie, L., Tan, C., Yan, L.-J., Ju, X., Liu, R., Qian, H., Marvin, M. A., Goldberg, M. S., She, H., Mao, Z., Simpkins, J. W., & Yang, S.-H. (2011). Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. Journal of Biological Chemistry, 286(18), 16504–16515. Study
Zuschlag, Z. D., Warren, M. W., & Schultz, S. K. (2018). Serotonin toxicity and urinary analgesics: A case report and systematic literature review of methylene blue-induced serotonin syndrome. Psychosomatics, 59(6), 539–546. Study